Adaptimmune logo

Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.

200 employees · est. 2008 · Abingdon, United Kingdom

VS
Allogene Therapeutics logo

Allogene Therapeutics

A biotechnology company catalyzing cancer treatment through the development of CAR T therapy

214 employees · est. 2017 · South San Francisco, United...

Adaptimmune is the older company (2008 vs 2017); Allogene Therapeutics is the larger of the two.

Side-by-Side Comparison

Adaptimmune Allogene Therapeutics
Founded
2008 older 2017
Headquarters
Abingdon, United Kingdom South San Francisco, United States
Employees
200 214 larger
Industry
Biopharma, Biotechnology, Health Care Biotechnology
Funding Stage
Post Ipo Debt IPO
Total Funding
$499.50M $1.05B
Funding Rounds
9 4
Services
Development of T-cell therapies, Pipeline management of cell therapies, Sale and licensing of cell therapies, Biotechnological research, Clinical trials Development of CAR T cell products, Clinical trial management, Gene editing and engineering, Manufacturing of allogeneic therapies, Therapeutic innovation for cancer and autoimmune diseases
Target Customers
Cancer patients, Healthcare professionals, Biopharmaceutical companies, Medical researchers Patients with blood cancers, Patients with solid tumors, Patients with autoimmune diseases, Healthcare providers, Biopharmaceutical partners
Taxonomy
Cell Therapy, Cancer Treatment, T Cell Therapies, Preclinical Research, Clinical Development, Translational Sciences, Autologous Manufacturing, Allogeneic Manufacturing, T Cell Receptor Proteins, Affinity T Cell Receptor, Immunotherapy, Infectious Disease Treatment, HIV Therapy, Corporate Operations Clinical-stage, Cancer Treatment, Immunotherapy, CAR T Therapy, AlloCAR T Products, Allogeneic Therapies, Oncology, Autoimmune Disease, Cell Therapy, Therapy Development, Biopharmaceuticals, Medical Innovation, South San Francisco
Website
adaptimmune.com allogene.com
Adaptimmune logo

About Adaptimmune

Adaptimmune stands as a pioneering entity in the biopharmaceutical landscape, specializing in cell therapies designed to revolutionize cancer treatment. With its strong presence in four biotechnology hubs across the U.K. and U.S., the company showcases comprehensive competencies ranging from preclin...

Allogene Therapeutics logo

About Allogene Therapeutics

Allogene Therapeutics, based in South San Francisco, is a clinical-stage biotechnology company spearheading the evolution of cancer treatment with its innovative AlloCAR T products. Founded in 2017, the company is at the forefront of developing allogeneic chimeric antigen receptor T cell therapies,...

We will tell you when either one moves

BounceWatch watches Adaptimmune and Allogene Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Adaptimmune and Allogene Therapeutics — by email.

Frequently Asked Questions

Adaptimmune — Designing and delivering cell therapies to transform the lives of people with cancer.. Allogene Therapeutics — A biotechnology company catalyzing cancer treatment through the development of CAR T therapy. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Adaptimmune has raised $499.50M while Allogene Therapeutics has raised $1.05B.
Adaptimmune and Allogene Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Adaptimmune with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Adaptimmune on 11 Mar 2026, and Allogene Therapeutics on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy